ARTICLE | Clinical News
Xgeva regulatory update
February 1, 2017 9:43 PM UTC
Amgen withdrew an MAA from EMA for Xgeva denosumab seeking to expand the label to include treatment of hypercalcemia of malignancy refractory to IV bisphosphonate therapy. The company said it withdrew...
BCIQ Company Profiles
BCIQ Target Profiles